GlassScriptPhysician profile
Jeffrey Tamsing
NPI 1457518680
$179,624.79
in general payments reported to CMS, 2019-2025
96 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $28K · 2021: $11K · 2022: $12K · 2023: $26K · 2024: $29K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $15K · Consulting Fee: $4,875 · Travel and Lodging: $4,170 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,712.50 |
| Food and Beverage | $14,521.53 |
| Consulting Fee | $4,875.00 |
| Travel and Lodging | $4,169.52 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $89,225.05 | 2019-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $39,044.10 | 2019-2025 | Kisunla, Reyvow, Emgality |
| Argenx US, INC. | $25,006.94 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Abbvie INC. | $3,145.69 | 2019-2025 | Botox, Ubrelvy, Qulipta |
| Amgen INC. | $2,989.29 | 2019-2025 | Uplizna, Aimovig |
| Ucb, INC. | $1,244.90 | 2019-2025 | Zilbrysq, Rystiggo, Fintepla |
| Pfizer INC. | $1,207.96 | 2019-2025 | |
| Celgene Corporation | $1,166.64 | 2020-2025 | Zeposia |
| Neurocrine Biosciences, INC. | $1,112.38 | 2019-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $1,096.02 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,089.52 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $1,082.25 | 2019-2025 | Vyepti, Rexulti |
| Biogen, INC. | $1,059.05 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Tanabe Pharma America, INC. | $820.76 | 2019-2025 | Radicava |
| Allergan, INC. | $819.31 | 2019-2022 |
Show all 96 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Tamsing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.